Marksans Pharma rises on receiving EIR from USFDA for Goa facility

07 Jun 2019 Evaluate

Marksans Pharma is currently trading at Rs. 22.95, up by 0.25 points or 1.10% from its previous closing of Rs. 22.70 on the BSE.

The scrip opened at Rs. 23.00 and has touched a high and low of Rs. 23.60 and Rs. 22.80 respectively. So far 41707 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 40.55 on 04-Sep-2018 and a 52 week low of Rs. 20.95 on 14-May-2019.

Last one week high and low of the scrip stood at Rs. 23.60 and Rs. 21.65 respectively. The current market cap of the company is Rs. 929.14 crore.

The promoters holding in the company stood at 48.25%, while Institutions and Non-Institutions held 4.07% and 47.68% respectively.

Marksans Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Goa facility. The inspection at the company's facility was carried out from February 25 to March 06, 2019.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma Share Price

183.00 -0.95 (-0.52%)
08-Dec-2025 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×